Ich stimme zu, dass diese Seite Cookies verwende. Weitere Informationen finden Sie unter unseren Datenschutzerklärungen .
X
Banerji, V
620  Ergebnisse:
Personensuche X
?
1

PL02.1.A DELINEATING AND TARGETING A NOVEL METABOLISM-BASED..:

Martell, E ; Kuzmychova, H ; Kaul, E...
Neuro-Oncology.  25 (2023)  Supplement_2 - p. ii1-ii2 , 2023
Link: https://doi.org/10.1093/..
 
?
2

P666: ACALABRUTINIB ± OBINUTUZUMAB VS OBINUTUZUMAB + CHLORA..:

Sharman, J. P. ; Egyed, M. ; Jurczak, W....
HemaSphere.  6 (2022)  - p. 564-565 , 2022
Link: https://doi.org/10.1097/..
 
?
3

Rapid improvement in symptoms and physical function followi..:

Ishdorj, G. ; Nugent, Z. ; Squires, M....
Leukemia Research.  109 (2021)  - p. 106628 , 2021
Link: https://doi.org/10.1016/..
 
?
4

Topic: AS02-Epidemiology:

Brailovski, E. ; Mozessohn, L. ; Abel, G....
Leukemia Research.  108 (2021)  - p. 106681.9 , 2021
Link: https://doi.org/10.1016/..
 
?
5

CN4 Patient-Reported Outcomes from the Phase 3, Randomized ..:

Walker, P. ; Sharman, J.P. ; Jurczak, W....
Value in Health.  24 (2021)  - p. S3-S4 , 2021
Link: https://doi.org/10.1016/..
 
?
6

PD-1 Inhibition in Malignant Melanoma and Lack of Clinical ..:

Landego, I. ; Hewitt, D. ; Hibbert, I....
Current Oncology.  27 (2020)  3 - p. 169-172 , 2020
Link: https://doi.org/10.3747/..
 
?
7

Updates from the American Society of Hematology 2019 Annual..:

Banerji, V. ; Anglin, P. ; Christofides, A...
Current Oncology.  27 (2020)  2 - p. 231-245 , 2020
Link: https://doi.org/10.3747/..
 
?
8

An MDS-specific frailty index based on cumulative deficits ..:

Starkman, R. ; Alibhai, S. ; Wells, R. A....
Leukemia.  34 (2019)  5 - p. 1394-1406 , 2019
Link: https://doi.org/10.1038/..
 
?
9

PCN237 IMPACT OF ORAL TARGETED THERAPY ON THE ECONOMIC BURD..:

Lachaine, J. ; Beauchemin, C. ; Guinan, K....
Value in Health.  22 (2019)  - p. S481-S482 , 2019
Link: https://doi.org/10.1016/..
 
?
10

Complete Resolution of Chylopericardium after Chemotherapy ..:

Morris, A.L. ; Colbourne, T. ; Kirkpatrick, I..
Current Oncology.  26 (2019)  5 - p. 696-699 , 2019
Link: https://doi.org/10.3747/..
 
?
11

Descriptive Analysis of Dosing and Outcomes for Patients wi..:

Uminski, K. ; Brown, K. ; Bucher, O....
Current Oncology.  26 (2019)  5 - p. 610-617 , 2019
Link: https://doi.org/10.3747/..
 
?
12

Canadian Evidence-Based Guideline for the First-Line Treatm..:

Owen, C. ; Gerrie, A. S. ; Banerji, V....
Current Oncology.  25 (2018)  5 - p. 461-474 , 2018
Link: https://doi.org/10.3747/..
 
?
13

Gefitinib targets ZAP-70-expressing chronic lymphocytic leu..:

Dielschneider, R F ; Xiao, W ; Yoon, J-Y...
Cell Death & Disease.  5 (2014)  10 - p. e1439-e1439 , 2014
Link: https://doi.org/10.1038/..
 
?
14

Increased risk of second malignancies in chronic lymphocyti..:

Beiggi, S ; Johnston, J B ; Seftel, M D...
British Journal of Cancer.  109 (2013)  5 - p. 1287-1290 , 2013
Link: https://doi.org/10.1038/..
 
?
15

High incidence of chronic lymphocytic leukemia (CLL) diagno..:

Seftel, M.D. ; Demers, A.A. ; Banerji, V....
Leukemia Research.  33 (2009)  11 - p. 1463-1468 , 2009
Link: https://doi.org/10.1016/..
 
1-15